Malathi Narasimhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Malathi Narasimhan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alan M. Punnoose
Center for Regenerative Medicine and Stem Cell Research Central Research Facility Sri Ramachandra University and Research Institute Chennai India
1 shared publicationAmol A Raje
Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India
1 shared publicationAyesha Tabassum
Department of Oral and Maxillofacial Pathology, Sri Ramachandra Dental College, Faculty of Dental Sciences of Higher Education, Chennai, Tamil Nadu, India
1 shared publicationD. Chamundeeswari
Faculty of Pharmacy, Meenakshi Academy of Higher Education and Research, Chennai, India
1 shared publication- Divyambika Catakapatri Venugopal
Department of Oral Medicine and Radiology, Sri Ramachandra Dental College and Hospital, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, India
1 shared publication Himavanth Reddy Kambalachenu
Department of Biomedical Sciences Sri Ramachandra University and Research Institute Chennai India
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Oral and Maxillofacial Pathology
- Vol. 29 (1) , 24-29
Evaluation of CD20 in labial minor salivary gland biopsies in Sjogren’s syndrome
Context: Sjogren’s syndrome (SjS) is an auto-immune disease with a chronic inflammation causing dysfunction of salivary and lacrimal glands, leading to dry eyes and dry mouth. Focal lymphocytic sialadenitis (FLS) and focus score (FS) are significant diagnostic criteria in SjS. Aims: To evaluate the FLS and FS and quantify FS in H&E sections of normal salivary gland, inflammatory conditions, and SjS group. Settings and Design: A total of 60 cases were included and divided equally among the groups – SjS, inflammatory conditions, and normal salivary gland. Methods and Material: The clinical symptoms, associated disease, and serological tests (ANA, SSA, SSB, RF) were obtained from the records of the patient. Immunohistochemistry (IHC) staining was done (anti-CD20 monoclonal antibody). All the H&E and IHC slides were assessed by independent observers and were taken up for evaluation. Results and Conclusions: In H&E sections, FLS and FS were found only in the SjS patients and not in normal and inflammatory conditions. CD20 expression was found to be positive in 55% of SjS cases but negative in the normal and inflammatory groups. FS had been upgraded in IHC CD20 staining. FLS and FSs should be strictly evaluated according to the criteria. It was found only in SjS patients and not in normal and inflammatory conditions. Furthermore, CD20 can be used as an adjunct marker to decide the theranostic and prognostic markers of SjS. The results showed that criteria for scoring FS should be strictly followed and CD20 IHC can be used as a prognostic marker.
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Oral and Maxillofacial Pathology
- Vol. 29 (1) , 24-29
Open AccessEvaluation of CD20 in labial minor salivary gland biopsies in Sjogren’s syndrome
Context: Sjogren’s syndrome (SjS) is an auto-immune disease with a chronic inflammation causing dysfunction of salivary and lacrimal glands, leading to dry eyes and dry mouth. Focal lymphocytic sialadenitis (FLS) and focus score (FS) are significant diagnostic criteria in SjS. Aims: To evaluate the FLS and FS and quantify FS in H&E sections of normal salivary gland, inflammatory conditions, and SjS group. Settings and Design: A total of 60 cases were included and divided equally among the groups – SjS, inflammatory conditions, and normal salivary gland. Methods and Material: The clinical symptoms, associated disease, and serological tests (ANA, SSA, SSB, RF) were obtained from the records of the patient. Immunohistochemistry (IHC) staining was done (anti-CD20 monoclonal antibody). All the H&E and IHC slides were assessed by independent observers and were taken up for evaluation. Results and Conclusions: In H&E sections, FLS and FS were found only in the SjS patients and not in normal and inflammatory conditions. CD20 expression was found to be positive in 55% of SjS cases but negative in the normal and inflammatory groups. FS had been upgraded in IHC CD20 staining. FLS and FSs should be strictly evaluated according to the criteria. It was found only in SjS patients and not in normal and inflammatory conditions. Furthermore, CD20 can be used as an adjunct marker to decide the theranostic and prognostic markers of SjS. The results showed that criteria for scoring FS should be strictly followed and CD20 IHC can be used as a prognostic marker.
- 26 August 2024
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 17 (8) , 3757-3763
Pharmacokinetic and Pharmacodynamic Interactions of Momordica charantia extract with Glibenclamide in Streptozotocin induced Diabetic rats
Diabetes mellitus (DM) has emerged as a leading global health problem. Diabetes is estimated to affect 425 million adults globally. Majority of diabetic patients take herbal medicines as supplement for the treatment of diabetes. The combined use of herbs and modern synthetic medicine has increased the possibility of pharmacokinetic (PK) and pharmacodynamic (PD) interactions. Momordica charantia (MC) commonly known as bitter melon/bitter gourd, is globally marketed for treatment of diabetes. Many diabetic patients consume MC extract along with antidiabetic drugs for better therapeutic effect with or without knowledge of health care provider.The current study evaluated PKPD herb-interaction of MC extract with glibenclamide (GLB) following oral administration either alone or in combination with MC extract for 28-consequative days. MC extract co-administratioin showed increased plasma exposure of GLB on Day-28 compared to glibenclamide alone treated groups with similar dosing regimen. Glibenclamide upon co-administration with MC extract showed improved pharmacodynamic parameters compared to glibenclamide alone treated groups suggesting synergistic or additive effect. Physician can reduce the glibenclamide dose in diabetic patients if they are taking MC as supplement.
- 26 August 2024
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 17 (8) , 3757-3763
Pharmacokinetic and Pharmacodynamic Interactions of Momordica charantia extract with Glibenclamide in Streptozotocin induced Diabetic rats
Diabetes mellitus (DM) has emerged as a leading global health problem. Diabetes is estimated to affect 425 million adults globally. Majority of diabetic patients take herbal medicines as supplement for the treatment of diabetes. The combined use of herbs and modern synthetic medicine has increased the possibility of pharmacokinetic (PK) and pharmacodynamic (PD) interactions. Momordica charantia (MC) commonly known as bitter melon/bitter gourd, is globally marketed for treatment of diabetes. Many diabetic patients consume MC extract along with antidiabetic drugs for better therapeutic effect with or without knowledge of health care provider.The current study evaluated PKPD herb-interaction of MC extract with glibenclamide (GLB) following oral administration either alone or in combination with MC extract for 28-consequative days. MC extract co-administratioin showed increased plasma exposure of GLB on Day-28 compared to glibenclamide alone treated groups with similar dosing regimen. Glibenclamide upon co-administration with MC extract showed improved pharmacodynamic parameters compared to glibenclamide alone treated groups suggesting synergistic or additive effect. Physician can reduce the glibenclamide dose in diabetic patients if they are taking MC as supplement.
- 28 May 2024
- Published by Wiley in Oral Diseases
- Vol. 31 (5) , 1503-1516
Natural products and diet for the prevention of oral cancer: Research from south and southeast Asia
Medicinal plants are of prime importance in the discovery of drugs. They are an inherent source of naturally available phytochemicals that can help in the prevention and treatment of several diseases including cancer. This article reviews the experimental and clinical evidence of phytochemicals available in natural dietary products that are used in everyday life across South Asia and South‐East Asia for their perceived effectiveness in the management of Potentially Malignant Disorders and prevention of Oral Cancer. The review also highlights the active phytometabolites, their in vitro anti‐proliferative properties and targeted signalling pathways, biological activities in in vivo models and translative potential for clinical trials in humans.
- 28 May 2024
- Published by Wiley in Oral Diseases
- Vol. 31 (5) , 1503-1516
Natural products and diet for the prevention of oral cancer: Research from south and southeast Asia
Medicinal plants are of prime importance in the discovery of drugs. They are an inherent source of naturally available phytochemicals that can help in the prevention and treatment of several diseases including cancer. This article reviews the experimental and clinical evidence of phytochemicals available in natural dietary products that are used in everyday life across South Asia and South‐East Asia for their perceived effectiveness in the management of Potentially Malignant Disorders and prevention of Oral Cancer. The review also highlights the active phytometabolites, their in vitro anti‐proliferative properties and targeted signalling pathways, biological activities in in vivo models and translative potential for clinical trials in humans.
- Open Access
- 23 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8)
Prevalence of Common Clinically Manifested Developmental Anomalies of the Oral Cavity Among Adults – An Epidemiological Study in a South Indian Population
Developmental anomalies are malformation which arises due to the disturbances during the development of the organs. Although there have been many studies that have described the prevalence of these anomalies in the oral cavity, none have specified the prevalence of clinically manifested anomalies and their distribution between gender. In this study, 500 patients aged 18 to 50 years were screened for clinically manifested developmental anomalies. These were then divided based on age, sex, and jaws, which were then analyzed using a chi-square test and tabulated. We detected anomalies in 12.2% of the study population. Supernumerary teeth were the most prevalent anomaly detected (4.25%). The frequency of developmental anomalies was higher in men (57.1%). Supernumerary teeth were the most widely recognized anomaly. Other anomalies identified were related to the shape and size of teeth. These anomalies can lead to severe orofacial problems. Therefore, proper care of these anomalies should be taken.
- 23 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8)
Open AccessPrevalence of Common Clinically Manifested Developmental Anomalies of the Oral Cavity Among Adults – An Epidemiological Study in a South Indian Population
Developmental anomalies are malformation which arises due to the disturbances during the development of the organs. Although there have been many studies that have described the prevalence of these anomalies in the oral cavity, none have specified the prevalence of clinically manifested anomalies and their distribution between gender. In this study, 500 patients aged 18 to 50 years were screened for clinically manifested developmental anomalies. These were then divided based on age, sex, and jaws, which were then analyzed using a chi-square test and tabulated. We detected anomalies in 12.2% of the study population. Supernumerary teeth were the most prevalent anomaly detected (4.25%). The frequency of developmental anomalies was higher in men (57.1%). Supernumerary teeth were the most widely recognized anomaly. Other anomalies identified were related to the shape and size of teeth. These anomalies can lead to severe orofacial problems. Therefore, proper care of these anomalies should be taken.
- 3 February 2016
- Published by Wiley in Journal of Investigative and Clinical Dentistry
- Vol. 8 (2)
Antifibrotic effect of Centella asiatica Linn and asiatic acid on arecoline‐induced fibrosis in human buccal fibroblasts
Aim: The aim of the present study was to investigate the in vitro antifibrogenic effects of Centella asiatica Linn (CA) and its bioactive triterpene aglycone asiatic acid (AA) on arecoline‐induced fibrosis in primary human buccal fibroblasts (HBF).Methods: An ethanolic extract of CA was prepared, and AA was purchased commercially. High‐performance thin‐layer chromatography (HPTLC) was performed to quantify AA in the CA extract; colorimetric assay (3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5‐diphenyltetrazolium bromide) was performed to determine an half‐maximal inhibitory concentration. HBF were cultured and stimulated with arecoline. The inhibitory effects of CA and AA at different concentrations were assessed using gene‐expression studies on fibrosis‐related markers: transforming growth factor‐β1, collagen 1 type 2, and collagen 3 type 1. The stimulatory effect of arecoline and the inhibitory effect of AA on fibroblast morphology and extracellular matrix were assessed qualitatively using Masson trichrome stain.Results: The HPTLC analysis determined 1.2% AA per 100 g of CA extract. Arecoline produced a concentration‐dependent increase in the fibrotic markers, treatment with CA significantly downregulated fibrotic markers at higher concentrations, and AA downregulated at lower concentrations. Arecoline altered fibroblast morphology and stained strongly positive for collagen, and AA treatment regained fibroblast morphology with faint collagen staining.Conclusion: CA and AA can be used as antifibrotic agents.
- 3 February 2016
- Published by Wiley in Journal of Investigative and Clinical Dentistry
- Vol. 8 (2)
Antifibrotic effect of Centella asiatica Linn and asiatic acid on arecoline‐induced fibrosis in human buccal fibroblasts
Aim: The aim of the present study was to investigate the in vitro antifibrogenic effects of Centella asiatica Linn (CA) and its bioactive triterpene aglycone asiatic acid (AA) on arecoline‐induced fibrosis in primary human buccal fibroblasts (HBF).Methods: An ethanolic extract of CA was prepared, and AA was purchased commercially. High‐performance thin‐layer chromatography (HPTLC) was performed to quantify AA in the CA extract; colorimetric assay (3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5‐diphenyltetrazolium bromide) was performed to determine an half‐maximal inhibitory concentration. HBF were cultured and stimulated with arecoline. The inhibitory effects of CA and AA at different concentrations were assessed using gene‐expression studies on fibrosis‐related markers: transforming growth factor‐β1, collagen 1 type 2, and collagen 3 type 1. The stimulatory effect of arecoline and the inhibitory effect of AA on fibroblast morphology and extracellular matrix were assessed qualitatively using Masson trichrome stain.Results: The HPTLC analysis determined 1.2% AA per 100 g of CA extract. Arecoline produced a concentration‐dependent increase in the fibrotic markers, treatment with CA significantly downregulated fibrotic markers at higher concentrations, and AA downregulated at lower concentrations. Arecoline altered fibroblast morphology and stained strongly positive for collagen, and AA treatment regained fibroblast morphology with faint collagen staining.Conclusion: CA and AA can be used as antifibrotic agents.